Health and Healthcare
Cramer's #3 Speculative Stock for 2007
Published:
Last Updated:
Tonight Cramer continued his quest of delivering his favorite TOP 3 SPECULATIVE STOCKS FOR 2007. Cramer started off with his #3 pick, or the second runner up for the speculative stocks.
Savient Pharma (SVNT) is his #1 pick. He said it is up $4.00 and has been on a tear. It is up against competition, and you can’t put more than 20% of your mad Money in any speculative stock and he thinks you need a basket of speculative stocks. With 20% geared toward speculative stocks, you should still have 4 others. Out of these you can expect one to scream and one to go bust. Cramer says management is good because they sold off a drug for more than it was worth then cut the number of shares with a Dutch tender. Their phase III gout drug looks promising and Cramer said there hasn’t been a gout treatment in about 40 years and there are 3 to 5 million Americans with gout. Phase II results were amazing, and if they have 35% market penetration he thinks it will be $200 million to $400 million and the stock could double.
Below are his picks from Wednesday and Thursday for Growth and Value Picks for 2007:
#1 growth pick is the New York Stock Exchange (NYSE).
#2 is Apple (AAPL).
#3 is Cisco Systems (CSCO).
If you want to read through to the top VALUE PICKS for 2007 that Cramer gave on Wednesday night, here is the list:
1) Altria (MO)
2) Goldman Sachs (GS)
3) Halliburton (HAL)
Jon C. Ogg
January 5, 2007
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.